ABSTRACT Treatment of neurodegenerative disease is entering a new era where direct intracerebral delivery of therapeutic factors aims to restore normality to dysfunctional circuits.
4, 7, and 14 days post-transplantation. Brains were analysed to determine in situ polymerisation and biodegradability of the fibrin scaffold, GDNF release from transplanted GDNF-MSCs, survival of the GDNF-MSCs graft and the host's immune response to the transplant. This study found that fibrin scaffold was adaptable to intra-cerebral delivery with successful polymerisation of the fibrin scaffold in situ. Inclusion of the fibrin scaffold was not detrimental to cell survival nor did it impede neurotrophin release from entrapped cells.
Importantly, the inclusion of the fibrin scaffold was associated with a reduced host astroglial and microglial response compared to cells alone indicative of a favourable biocompatibility profile. Overall, fibrin represents an adaptable scaffold for inclusion in a minimally invasive cell-based therapeutic approach for neurodegenerative diseases.
TEXT Introduction:
Parkinson's disease is a progressive neurodegenerative movement disorder that affects an estimated 1.2 million people in Europe 1 . Notwithstanding the severe impact that the disease has on the patients' quality of life, Parkinson's disease constitutes a major health economic challenge in terms of direct medical costs as well as in-direct costs from reduced employment 1, 2 . As the elderly population grows, the incidence of Parkinson's disease is set to increase substantially in the coming decades 2 . Such projections give a renewed impetus for the need to develop innovative treatment approaches to address the underlying neurodegeneration in an effort to slow disease progression 3 .
Therapeutic delivery to the central nervous system (CNS) poses significant challenges for researchers. Unsuccessful delivery approaches for disease modulating interventions continues to hinder the clinical realisation of promising therapeutic candidates. One of the most exciting novel therapeutic approaches to emerge for the treatment of Parkinson's disease has been the disease modulating neurotrophic factor, glial cell line-derived neurotrophic factor (GDNF) 4 .
Extremely promising pre-clinical [5] [6] [7] [8] and open-label clinical trials [9] [10] [11] , confirming the neuroprotective role of GDNF on dopaminergic neurons, renewed enthusiasm that disease modulating approaches were within reach. Unfortunately, issues related to the delivery of GDNF undoubtedly contributed towards the failure to reach satisfactory clinical outcome measures in a double-blind placebo-controlled study where patients received intra-putamenal infusion of recombinant GDNF via implanted catheters 12, 13 . Thus, clinical realisation of GDNFs potential appears to be intrinsically related to the successful development of an effective intra-cerebral delivery platform.
In this regard, ex vivo gene therapy, where cells are engineered to produce GDNF, may prove a more effective strategy for providing local and sustained delivery of GDNF than simple brain diffusion. Bone marrow-derived mesenchymal stem cells (MSCs) possess numerous desirable characteristics for clinical application given their relatively hypo-immunogenic profile [14] [15] [16] [17] [18] as well as their ease of isolation, expansion capacity and amenability to genetic manipulation [19] [20] [21] [22] . Importantly, stereotaxic injection of autologous MSCs to Parkinson's disease patients in an open-label trial was not associated with any serious adverse events 23 and highlights the advanced phase that this novel therapeutic concept has reached in a relatively short time frame.
As with all novel therapeutic approaches, systematic and incremental pre-clinical evaluation is essential in order to predict potential caveats to successful clinical translation. While we have shown that virally manipulated, GDNF over-expressing MSCs offer significant potential for the delivery of neurotrophic support to the Parkinsonian rat brain 24, 25 , successful clinical translation will undoubtedly be hindered by the poor survival of MSCs following transplantation 16, 24 . This concern is further corroborated by a recent study where autologous MSCs genetically engineered to over-express GDNF were unilaterally transplanted into the striatum and substantia nigra of cynomolgus monkeys 26 . While the transplanted GDNF overexpressing MSCs unquestionably provided protection against MPTP-induced neuronal damage (sparing contralateral limb motor function and enhancing striatal dopamine uptake), approximately only 10% of the engrafted cells remained eleven weeks post-transplantation 26 .
The limited survival of the GDNF-expressing MSCs may explain why low to non-detectable concentrations of GDNF were recorded in the post-mortem tissue. Thus, strategies aimed at improving the survival of GDNF-expressing MSCs following transplantation to the brain are required in order to ensure the continued advancement with this promising neurotrophin delivery approach.
One such effort to improve MSCs survival following transplantation is to couple the cell engraftment procedure with a biomaterial scaffold thereby providing a physical substrate upon which to complex pro-survival factors. To expedite the development of such a complimentary transplantation scaffold, it would be advantageous to utilise a biomaterial that is commercially available, clinically accepted and has significant pre-clinical data available to substantiate its safety profile. One such material fulfilling these criteria is fibrin, the biologically derived matrix which occurs during the wound healing cascade. Fibrin has favourable architectural and surface properties which make it a desirable material upon which to build a multimodal pro-survival matrix. Indeed, pre-clinical studies have illustrated the capacity of fibrin to facilitate protein 27-33 and gene delivery [34] [35] [36] [37] [38] [39] [40] in vivo. Moreover, fibrin has been evaluated as an adjunctive material to aid cell transplantation [41] [42] [43] further highlighting its potential utility as a complimentary transplantation material.
Fibrin is formed through the polymerisation of the soluble precursor molecule fibrinogen 44 , a process that is initiated by the serine protease thrombin. As the dual component fibrin matrix system necessitates the mixing of fibrinogen with thrombin to yield the fibrin scaffold in situ, fibrin has traditionally been evaluated in easily accessible compartments such as the spinal cord 45 , peripheral nerve 46 or directly to the brain surface 47 . In order to be considered for integration into a neurodegenerative cell-based therapeutic approach, fibrin delivery to the CNS must be minimally invasive and preferably injectable. Therefore, this study sought to determine if a commercially available, clinically accepted fibrin source could be utilised as an adjunct to intra-cerebral cell transplantation without evoking an adverse host or stem cell response.
Experimental Section: 
Experimental Design
Sixteen male Sprague-Dawley rats received bilateral intra-striatal transplants of 30,000
GDNF-transduced GFP-MSCs (hereafter referred to as GDNF-MSCs) delivered in either control transplantation medium (n=8 rats) or a fibrin scaffold (n=8 rats). Rats were sacrificed by anaesthetic overdose and transcardial fixation at 1, 4, 7, and 14 days post-transplantation (n=2 rats per group per time-point yielding n=4 independent transplantation sites per group per time point). Brains were analysed to determine fibrin scaffold in situ polymerisation and biodegradability, GDNF release from transplanted GDNF-MSCs and the host's immune response to the transplant using immunohistochemistry. Survival of the GDNF-MSC graft was studied using fluorescent microscopy.
Mesenchymal Stem Cell Isolation and Expansion
Green fluorescent protein MSCs (GFP-MSCs) were isolated from the bone marrow of 8-to 12-week-old Sprague-Dawley transgenic rats (extracted from the "green rat" SD-Tg (CAG-EGFP) CZ-004Osb 48, 49 ). Briefly, after euthanasia by CO 2 inhalation, femora and tibiae were 
Tissue Processing
Rats were deeply anaesthetised by pentobarbital injection (100 mg kg -1 i.p.) and transcardially perfused with 100 ml of heparinised saline (5000 units L -1 ) followed by 150 ml of ice cold 4% paraformaldehyde in phosphate buffer. Brains were removed and post-fixed for four hours at room temperature before transferring to 25% sucrose in phosphate buffer.
Serial coronal brain sections (30 µm) were cut using a freezing stage sledge microtome (Bright, UK).
Peroxidase-based Immunohistochemistry
Immunohistochemical staining for fibrin scaffold, GDNF, OX-42 and GFAP was completed on a 1:12 series of free floating sections using a peroxidise-based method as described previously 24, 52 . For each individual antigenic target, all control and treatment groups were processed at the same time to avoid heterogeneity between antibody solutions. In brief, endogenous peroxidase activity was quenched using a solution of 3% hydrogen peroxide/10% methanol in distilled water. Non-specific antibody binding was blocked using 3% normal serum in Tris-buffered saline (TBS) with 0.2% Triton X-100 at room temperature for 1 hour. Sections were incubated overnight at room temperature with the appropriate primary antibody diluted in TBS with 0.2% Triton X-100 (mouse anti-fibrin; goat anti-GDNF and the area or density of staining was measured using Image J software.
Statistical Analysis
GraphPad Prism 5 statistical software was used to analyse all data. All data are expressed as mean ± standard error of the mean (s.e.m). One-way ANOVA, using Newman-Keuls posthoc where appropriate, was used to assess the presence of the fibrin scaffold, while two-way ANOVA, with Bonferroni post-hoc test where appropriate, was used to analyse the impact of the fibrin scaffold on all other parameters over time.
Results:
In situ Polymerisation and Degradation Profile of the Fibrin Scaffold in the Rat Striatum
We first sought to determine if the fibrin scaffold was adaptable for intra-cerebral delivery.
Individual components of the fibrin system were injected directly into the striatum sequentially, with the fibrinogen component carrying the suspended cells injected initially followed by the thrombin component. Post-mortem histological analyses revealed the successful in situ formation of a fibrin scaffold within the striatum (Fig. 1A) .
Immunohistochemical staining targeting human fibrin revealed that a large fibrin scaffold was evident at the transplantation site day 1 post-transplantation (Fig. 1A&B) . By day 4 posttransplantation, the fibrin scaffold was still evident, however, the scaffold had reduced significantly in volume, indicative of resorption (Fig. 1B 1A&B ).
Fibrin Scaffold is Compatible with the Delivery of GDNF-MSCs to the Rat Striatum
We next sought to determine the impact that the fibrin scaffold had on GDNF-MSCs delivery and persistence at the graft site. Rats received intra-striatal injections of GDNF-MSCs delivered in either control medium or with the fibrin scaffold. Qualitatively, when delivered within the fibrin scaffold, the visual appearance of the GDNF-MSCs graft did not differ from cells delivered in control buffer ( Fig. 2A) . Cells formed a homogeneously dispersed graft at the transplant site (similar to those delivered in control buffer) indicating that the fibrin scaffold did not impede GDNF-MSCs delivery to and dispersal at the graft site ( Fig. 2A) .
Quantitatively, graft volume measurements indicated that GDNF-MSCs delivered within the fibrin scaffold had a similar survival profile as GDNF-MSCs delivered with control buffer.
While there was a trend for greater graft volume in the fibrin group, this did not differ significantly from control groups at any time-point ( Fig. 2B : Group, F (1, 24) =2.08; P=0.16, ns).
In line with previous published reports from our laboratory 24 , the volume of the graft declined significantly over time, with no negative impact from the presence of the fibrin scaffold evident at any time point (Fig. 2B : Time, F (3, 24) =18.52; P<0.001, by 2-way ANOVA with Newman-Keuls post-hoc test).
Fibrin Scaffold allows GDNF Diffusion from Entrapped Cells following Transplantation
We next sought to determine if the presence of the fibrin scaffold was conducive to neurotrophin diffusion from the entrapped GDNF-MSCs. Following transplantation to the brain, GDNF-MSCs released GDNF into the cerebral tissue with immunohistochemical staining revealing a large neurotrophic milieu surrounding the graft site ( Fig. 3A and B) . The volume of GDNF released from control and fibrin groups did not differ significantly at any time-point examined ( Fig. 3A and C: Group, F (1, 23) =1.39, P>0.05, ns.), demonstrating that the fibrin scaffold did not impede neurotrophin released from the transplanted GDNF-MSCs. In line with our previously published studies 24 , given that the GDNF-MSC grafts did not persist in the brain, the volume of GDNF released into the striatum from the transplanted cells declined significantly over time ( Discussion:
The present experiment sought to determine the utility of fibrin as an auxiliary biomaterial scaffold for delivery of neurotrophin over-expressing MSCs to the brain. To address this, adult rats received intra-striatal transplants of GDNF over-expressing MSCs delivered in either control transplantation buffer or combined with a fibrin scaffold. This study supports the supposition that the fibrin scaffold can be adapted for intra-cerebral delivery. Sequential injection of the individual components, fibrinogen and thrombin, resulted in the in situ formation of a fibrin scaffold in the striatum. Importantly, the therapeutic molecule, GDNF, was released into the striatal tissue from the stem cells contained within the fibrin scaffold.
Inclusion of a fibrin scaffold with the minimally invasive cell transplantation procedure did not induce an aversive host response and stem cell survival was not affected.
In order to be considered for integration in a cell-based therapy for neurodegenerative diseases, fibrin was tested in an intra-cerebral injectable format. Following sequential injection of fibrinogen and thrombin to the rat striatum, a large fibrin scaffold formed in the striatum indicative of successful in situ polymerization and confirming a viable delivery approach for the fibrin scaffold. Time-course analyses revealed that the fibrin scaffold had largely undergone resorption one week post-transplant, as expected 53, 54 . Proteases such as plasmin and scaffold metalloproteases are principally responsible for the degradation of fibrin scaffold in vivo 55 . Our experimental paradigm relied on the in situ polymerisation of the fibrin scaffold in order to gain proof-of-concept for the utility of fibrin in a minimally invasive transplantation approach. Therefore, it is likely that endogenous plasminogen from the host was incorporated into the scaffold accelerating the degradation profile compared to that of a pre-polymerised scaffold 53 . While the fibrin scaffold we delivered contained the protease inhibitor aprotinin, this small molecule rapidly diffuses out of matrices and therefore does not provide extended degradation protection. To address this limitation of the relatively rapid resorption of fibrin, Hubbell and colleagues have engineered an aprotinin variant that can be immobilized within fibrin thus significantly extending scaffold longevity 54 . Such an approach could be considered for integration into this system in an effort to prolong scaffold retention. Indeed, exploitation of differential fibrin degradation kinetics offers significant potential to develop a temporal release system to provide various pro-survival factors to promote stem cell survival over time. Our group has previously utilised this property to develop the fibrin-in-fibrin system, where highly cross-linked fibrin microspheres containing DNA are contained within the fibrin scaffold, with differential degradation processes allowing temporal release of encapsulated molecules 40 .
Microarchitecture also affects degradation of the fibrin scaffold by fibrinolysis 44 . Thrombin concentration at the time of gelation has a profound influence on fibrin clot structure. Low thrombin concentrations produce fibrin clots composed of thick, loosely-woven fibrin strands. Higher concentrations are composed of relatively thinner, more-tightly packed strands which are more resistant to fibrinolysis 44 . However, for the current application, the biocompatibility of the microarchitecture with cell viability dominated choice of fibrinogen:thrombin ratios above adapting the microarchitecture to address degradation profile 56 . The concentrations used in this study (60 mg ml -1 fibrinogen to 4 IU thrombin)
were compatible with cell delivery to the graft site and cell viability as no significant difference in graft persistence was observed when compared to control group. This was assessed using volumetric analysis of the GFP-expressing graft which we have previously shown to be a reliable method for assessing the overall survival of these cells in the rat brain 52 . Our laboratory has shown that the composition of this fibrin scaffold provides an excellent substrate to facilitate viral and non-viral therapeutic gene delivery 34, [36] [37] [38] [39] [40] .
Therefore, it is conceivable that this scaffold may be utilised as a platform to complex prosurvival factors to aid stem cell survival following transplantation. . These results suggest that while delivery of GDNF-MSCs within a fibrin scaffold did not improve GDNF secretion, it also did not impede release. All data shown as mean ± s.e.m. Scale bar 500 µm, 100 µm and 3mm Teresa.moloney@ndcn.ox.ac.uk
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